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Introduction
One of the ways in which the Medicines 
Authority protects public health is by 
minimising the risk to patients arising from 
the distribution of defective medicinal 
products. It achieves this by managing an 
assessment and communications system, 
between suppliers of medicinal products, the 
regulatory authorities and the users including 
patients, and when required oversees the 
removal of the defective medicinal products 
from the local market.
Holders of a manufacturer’s, importer’s 
and wholesale dealer’s licence are obliged 
to report to the Medicines Authority any 
defect in a medicinal product handled under 
their authorisation that could result in a 
recall or abnormal restriction in supply. This 
includes possibly faulty manufacture, product 
deterioration, detection of falsiﬁed medicines 
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or any other serious quality problems with a 
product.
Reporting of suspected product quality 
defects
Reports of suspected defects may also be 
sent to the authorities by other competent 
authorities, healthcare professionals and 
members of the general public.
If a member of the general public has 
reason to believe that their medicine is not 
of an acceptable quality, they should, in the 
ﬁrst instance, consult with their doctor or 
pharmacist who may then decide to refer 
the matter to the Medicines Authority, since 
the doctor or pharmacist may be in a better 
position to provide prompt advice and/
or reassurance to the patient. However, if 
it is not possible to speak to a doctor or 
pharmacist and the patient feels that the 
matter is urgent, they may contact the 
Medicines Authority directly.
The role of the Medicines Authority is 
to provide an assessment and communicate 
between suppliers of medicinal products, 
the regulatory authorities and the users. 
Where a defective medicine is considered to 
present a risk to public health, the marketing 
authorisation holder, the manufacturer 
or wholesale dealer as appropriate, is 
responsible for recalling the affected 
batch(es) or, in extreme cases, removing all 
batches of the product from the market. The 
Medicines Authority will normally support 
this action by the issue of a drug alert 
notiﬁcation to healthcare professionals.
Product recalls
A product recall is deﬁned as the retrieval 
from the marketplace of a batch or batches 
of any medicinal product which is/are the 
subject of a quality defect.
Product recalls are categorised according 
to the potential impact of the issue giving 
rise to the need for a recall, on patients 
and public health. There are three classes of 
recalls: 
s  Class I recalls – generally for critical 
quality defect issues. 
These are recalls which result 
from quality defects of medicinal 
products which are potentially life-
threatening or could cause a serious risk 
to health;
s  Class II recalls – generally for major 
quality defect issues. 
These are recalls due to quality 
defects which could cause illness or 
mistreatment but are not Class I;
s  Class III recalls  – generally for minor 
quality defect issues. 
These are recalls due to quality defects 
which are not likely to pose a signiﬁcant 
hazard to health but where a recall has 
been initiated for other reasons. 
In the case of Class I and Class II recalls, 
the Medicines Authority will notify regulators 
in other countries using the European Rapid 
Alert System.
Reporting of suspected quality defects
Suspected quality defects can be reported by 
using the Medicinal Product Defect Reporting 
Form.
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